VivoSeq
Immunology

Rheumatoid Arthritis (RA)

2

Pipeline Programs↗

6

Active Trials↗

4

Companies Involved↗

Rheumatoid Arthritis (RA) is an early-stage landscape with 2 programs across 4 companies. The most active players are Eli Lilly, Jacobio Pharmaceuticals Co., Ltd., Francisco J. Blanco.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

22/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

2 programs

Phase 1J

Jacobio Pharmaceuticals Co., Ltd.

1 program

Phase 2F

Francisco J. Blanco

0 programs

PreclinicalT

Tugba Civi Karaaslan

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

LY4213663

Eli Lilly

Phase 21

JAB-8263

Jacobio Pharmaceuticals Co., Ltd.

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

6

clinical trials

Recruiting4 · 67%
Not yet recruiting2 · 33%

Clinical Trials

Trial Activity

6 trials

Efficacy, Safety and Cost-effectiveness of a Biomarker-based Predictive Model for Persistent Remission in Rheumatoid Arthritis Patients Undergoing Biological Therapy Optimization
Recruiting·—·Preclinical·NCT07678112·184 enrolled
Comparison of Morning Versus Evening Oral Administration of a JAK Inhibitor in Rheumatoid Arthritis
Recruiting·CCentre Hospitalier Princesse Grace·N/A·NCT07674134·90 enrolled
BloodTrackR Usability and Concordance Study (BUCS)
Recruiting·UUniversity of Ulster·N/A·NCT07660029·20 enrolled
A Phase 1, Multicenter, Randomized, Placebo-Controlled, Investigator- and Participant-Blinded, Single- and Multiple-Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY4213663 in Healthy Participants, and Two Open-Label, Multiple-Dose Evaluations of LY4213663 in Patients With Rheumatoid Arthritis.
Recruiting·Eli Lilly logoEli Lilly·Phase 1·NCT07258849·141 enrolled
A Phase Randomized, Double-blind, Placebo-controlled Evaluate the Efficacy and Safety IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis
Not yet recruiting·JJacobio Pharmaceuticals Co., Ltd.·Phase 2·NCT07684157·32 enrolled
Effectiveness of a Mobile Application-Based Yoga and Meditation Program in Patients With Rheumatoid Arthritis: A Single-Blind Randomized Controlled Trial.
Not yet recruiting·—·Preclinical·NCT07666594·102 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)